Ionis announces Kyle Jenné returns as EVP Commercial; Onaiza Cadoret-Manier departs

IONIS PHARMACEUTICALS INC

Kyle Jenné rejoins as executive vice president, commercial, effective Feb 29, 2024.
Onaiza Cadoret-Manier, EVP chief global product strategy and operations officer, leaves for another opportunity.
Cadoret-Manier will remain full-time through March 15, 2024, then serve as advisor.
Advisory agreement pays $12,500/month through Sep 2024, then $6,250/month through Jan 10, 2025.

item 5.02 item 1.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kyle Jenné

executive vice president, commercial

IONS · IONIS PHARMACEUTICALS INC

Effective: 2024-02-29
Filed: February 29, 2024, 6:59 PM ET

Kyle Jenné has rejoined Ionis as executive vice president, commercial

Departed

Onaiza Cadoret-Manier

executive vice president, chief global product strategy and operations officer

IONS · IONIS PHARMACEUTICALS INC

Effective: 2024-03-15
Filed: February 29, 2024, 6:59 PM ET

Onaiza Cadoret-Manier, executive vice president, chief global product strategy and operations officer, is leaving the company to pursue another opportunity.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Kyle Jenné was appointed as executive vice president, commercial at IONIS PHARMACEUTICALS INC.

Action: rejoined
Role: executive vice president, commercial

Exact text from the filing

Kyle Jenné has rejoined Ionis as executive vice president, commercial

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Onaiza Cadoret-Manier departed as executive vice president, chief global product strategy and operations officer at IONIS PHARMACEUTICALS INC.

Action: leaving
Role: executive vice president, chief global product strategy and operations officer

Exact text from the filing

Onaiza Cadoret-Manier, executive vice president, chief global product strategy and operations officer, is leaving the company to pursue another opportunity.

View on SEC.gov

IONIS PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001140361-24-010288

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.